Carlo started his biotech journey as a founder and G7 Therapeutics as a spin-off from the University of Zurich. The company developed a technology for stabilization of G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. G7 therapeutics was acquired by Sosei Heptares in 2016. But Carlo didn’t rest. He co-founded Acthera Therapeutics in 2019 and is active as a mentor. He also co-founded inCephalo, where he is currently active as CEO. With inCephalo the team is driven to change the landscape of therapeutic options for brain tumours.